ARCHIVES

FDA Promises No More IND Disruptions Without “Very Valid Reasons,” Nears Agreement With NCI

This article is from The Cancer Letter archive.

Vol. 03 No. 15 | April 15, 1977

Download PDF Visit The Full Archive

Related Articles

Promising Results For Glivec In CML Continue, FDA Grants Priority Review

April 27, 2001

FTC Report Disagrees With Key Provision Of Biologics Bill Backed By Companies

June 12, 2009

Satcher Calls For Wider Use Of Smoking Prevention Efforts.

September 29, 2000

In Brief: Pursell Most Likely To Replace Conte, Foriend Of Cancer Program; DeVita Names Associate

February 15, 1991

In Brief: Hazleton Acquires Prime Labs, Primate Importer; Cullen UCLA Deputy Director

July 30, 1976

How Cancer Control Grants, Contracts Distributed By States

October 13, 1978